พบ "Digital Medicine"ทั้งหมด 196 ผลลัพธ์
Black mamba venom is ‘better painkiller’ than morphine
A painkiller as powerful as morphine, but without most of the side-effects, has been found in the deadly venom of the black mamba, say French scientists.The predator, which uses neurotoxins to paralyse and kill small animals, is one of the fastest and most dangerous snakes in Africa.However, tests o
Before Birth, Dad’s ID
It is an uncomfortable question that, in today’s world, is often asked by expectant mothers who had more than one male partner at the time they became pregnant. Who is the father?With more than half of births to women under 30 now out of wedlock, it is a question that may arise more often.Now blood
Balancing the right to know and the privacy of the patent system: a case study of oncology medicines in Thailand. (2013)
Balancing the right to know and the privacy of the patent system: a case study of oncology medicines in Thailand.
Inthira Yamabhai; Richard D. Smith
Abstract: This study aims to illustrate the processes to determine medicine patent status in developing countries by using oncology medicine in T
AstraZeneca starts new study of heart drug versus rival
(Reuters) – AstraZeneca is to conduct a new global clinical trial of key new heart drug Brilinta involving 11,500 patients with peripheral artery disease, Britain’s second biggest drugmaker said on Tuesday.Peripheral artery disease affects around 27 million people in Europe and North America, with s
Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified?
Abstract
Background and Objectives
The Health Intervention and Technology Assessment Program was commissioned to conduct a cost–utility and budget impact analysis of enzyme replacement therapy (ERT) for Gaucher disease types 1 and 3b. The findings from this assessment are to support the decision-m
Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified?
Abstract
Background and Objectives
The Health Intervention and Technology Assessment Program was commissioned to conduct a cost–utility and budget impact analysis of enzyme replacement therapy (ERT) for Gaucher disease types 1 and 3b. The findings from this assessment are to support the decision-m
Analysis: U.S. governors make risky political bet on healthcare funds
(Reuters) – Republican governors bent on rejecting the healthcare law’s expanded insurance coverage for millions of low-income Americans may see their gambit backfire if their party fails to sweep the November elections.Five governors have vowed to opt out of the Medicaid expansion for low-income pe
Alzheimer’s ‘early signs timeline developed’
Scientists have assembled a “timeline” of the unseen progress of Alzheimer’s before symptoms appear.A team at Washington University School of Medicine looked at families with a genetic risk of the disease.Writing in the New England Journal of Medicine, they say signs appeared up to 25 years before t
AIDS deaths worldwide drop as access to drugs improves
(Reuters) – Fewer people infected with HIV globally are dying as more of them get access to crucial antiretroviral drugs, particularly in sub-Saharan Africa, the United Nations AIDS program said on Wednesday.The United Nations estimates that about 34 million people are living with the human immunode
Advanced health biotechnologies in Thailand: State of the art, future trends and strategic preparation
Aiming at appropriate preparation for the future development of individualized and regenerative medicine (in particular, gene, stem cell and tissue engineering therapies), the Health Intervention and Technology Assessment (HITAP) program has agreed to conduct a study to provide an insight on elements necessary for national policymaking in Thailand.
10 / หน้า